Clinical experience with the use of novel cephalosporin/beta-lactamase inhibitor combinations among solid organ transplant recipients

Transpl Infect Dis. 2019 Oct;21(5):e13161. doi: 10.1111/tid.13161. Epub 2019 Aug 29.

Authors

Puja H Nambiar¹, Kyle D Brizendine², Vasilios Athans³, Eric Cober²

Affiliations

¹ Department of Medicine/Division of Infectious Disease, Ochsner Louisiana State University Health Sciences Center, Shreveport, Louisiana.
² Department of Infectious Disease, Cleveland Clinic, Cleveland, Ohio.
³ Department of Pharmacy, Hospital of the University of Pennsylvania, Philadlephia, Pennsylvania.

PMID: 31419340
DOI: 10.1111/tid.13161

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Cephalosporinase / therapeutic use*
Drug Resistance, Multiple, Bacterial
Drug Therapy, Combination
Enterobacteriaceae Infections / drug therapy*
Female
Humans
Male
Middle Aged
Organ Transplantation / adverse effects
Pseudomonas Infections / drug therapy*
Transplant Recipients / statistics & numerical data*
Treatment Outcome
beta-Lactamase Inhibitors / therapeutic use*

Substances

beta-Lactamase Inhibitors
Cephalosporinase